Season 8 | Episode 21
The recent FDA approval of oveporexton represents a major milestone in the treatment of narcolepsy type 1 and the culmination of decades of research into orexin and its critical role in regulating sleep and wakefulness. In this episode of Talking Sleep, host Dr. Seema Khosla is joined by Dr. Emmanuel Mignot, a longtime leader in narcolepsy research and co-recipient of the 2026 Lasker Award for research that helped uncover the role of orexin in narcolepsy.
Unlike existing therapies that primarily target the symptoms of narcolepsy, oveporexton is an orexin receptor 2 agonist designed to address the underlying loss of orexin signaling associated with narcolepsy type 1. Dr. Mignot shares his perspective on the science behind this new treatment approach and what the approval could mean for patients and clinicians. Topics include findings from clinical trials, the potential impact on excessive daytime sleepiness and cataplexy, dosing and safety considerations, and how an orexin-targeted therapy may fit into the evolving treatment landscape.
The episode also provides perspective on the scientific journey that made this advance possible. Research into the orexin system has transformed the understanding of narcolepsy and opened new possibilities for therapies that more directly address its underlying biology. The discussion considers the significance of translating those discoveries into a treatment for patients, as well as some of the questions clinicians may encounter as oveporexton enters clinical practice.
Looking beyond this approval, orexin agonists may have implications that extend beyond narcolepsy. Dr. Mignot offers insight into the continued evolution of orexin research and the potential for this growing area of sleep medicine to shape the future understanding and treatment of sleep and other medical disorders.
For sleep clinicians, this episode offers both a closer look at a new treatment option for narcolepsy type 1 and a broader perspective on how decades of scientific discovery can translate into meaningful advances in patient care.
Emmanuel Mignot, MD, PhD, is the Craig Reynolds Professor of Sleep Medicine in the Department of Psychiatry and Behavioral Sciences at Stanford University and director of the Stanford Center for Narcolepsy. A pioneering researcher in narcolepsy, his work helped uncover the role of hypocretin/orexin in the disorder and has shaped the understanding of its underlying biology. He is a recipient of the 2023 Breakthrough Prize in Life Sciences and the 2026 Albert Lasker Basic Medical Research Award. His research continues to focus on the neurobiology, genetics and immunology of narcolepsy and other sleep disorders.
I kept the emphasis on narcolepsy and orexin research because that directly connects his background to the oveporexton episode, while removing biographical details that aren’t as relevant for a short podcast guest bio.
